Osteoinductive small molecules: Growth factor alternatives for bone tissue engineering

Current Pharmaceutical Design

Volumn 19, Issue 19, 2013, Pages 3420-3428

  Aravamudhan, Aja ^a   Ramos, Daisy M ^a,b   Nip, Jonathan ^a   Subramanian, Aditi ^a,b   James, Roshan ^a   Harmon, Matthew D ^a,b   Yu, Xiaojun ^c   Kumbar, Sangamesh G ^a,b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c Stevens Institute of Technology   (United States)

Author keywords

Bone regeneration; Bone tissue engineering; Growth factors; Osteogenic; Signaling pathways; Small molecules; Stem cells

Indexed keywords

BONE MORPHOGENETIC PROTEIN; GROWTH FACTOR; MELATONIN; MITOGEN ACTIVATED PROTEIN KINASE; PURMORPHAMINE; RESVERATROL; SIRTUIN 1; UNCLASSIFIED DRUG; SIGNAL PEPTIDE;

ARTICLE; BONE DEVELOPMENT; BONE REGENERATION; CELL DIFFERENTIATION; OSSIFICATION; PRIORITY JOURNAL; STEM CELL; TISSUE ENGINEERING; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR LIBRARY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BONE REGENERATION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR STRUCTURE; OSTEOGENESIS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; TISSUE ENGINEERING;

EID: 84887369929     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319190008     Document Type: Article

References (97)

1. Valmikinathan CM, Chang W, Xu J, Yu X. Self assembled temperature responsive surfaces for generation of cell patches for bone tissue engineering. Biofabrication 2012; 4: 035006.
2. Kilian KA, Bugarija B, Lahn BT, Mrksich M. Geometric cues for directing the differentiation of mesenchymal stem cells. Proc Natl Acad Sci USA 2010; 107: 4872-7.
3. Bettinger CJ, Langer R, Borenstein JT. Engineering substrate topography at the micro-and nanoscale to control cell function. Angew Chem Int Ed Engl 2009; 48: 5406-15.
4. Ayala R, Zhang C, Yang D, et al. Engineering the cell-material interface for controlling stem cell adhesion, migration, and differentiation. Biomaterials 2011; 32: 3700-11.
5. Alves H, Dechering K, Van Blitterswijk C, De Boer J. Highthroughput assay for the identification of compounds regulating osteogenic differentiation of human mesenchymal stromal cells. PLoS One 2011; 6: e26678.
6. Arias JL. FM. Polysaccharides and Polyglycans in calcium carbonate based biomineralization. Chem. Rev. 2008; 108: 4475-82.
7. Wang J, Valmikinathan CM, Liu W, Laurencin CT, Yu X. Spiralstructured, nanofibrous, 3D scaffolds for bone tissue engineering. Journal of Biomedical Materials Research Part A 2010; 93A: 753-62.
8. Benoit DS, Schwartz MP, Durney AR, Anseth KS. Small functional groups for controlled differentiation of hydrogelencapsulated human mesenchymal stem cells. Nat Mater 2008; 7: 816-23.
9. Jasmin, Spray DC, Campos de Carvalho AC, Mendez-Otero R. Chemical induction of cardiac differentiation in p19 embryonal carcinoma stem cells. Stem Cells Dev 2010; 19: 403-12.
10. Liu X, He J, Zhang S, Wang XM, Liu HY, Cui FZ. Adipose stem cells controlled by surface chemistry. J Tissue Eng Regen Med 2011.
11. Murray P, Vasilev K, Fuente Mora C, et al. The potential of small chemical functional groups for directing the differentiation of kidney stem cells. Biochem Soc Trans 2010; 38: 1062-6.
12. Ren YJ, Zhang H, Huang H, et al. In vitro behavior of neural stem cells in response to different chemical functional groups. Biomaterials 2009; 30: 1036-44.
13. Boontheekul T, Hill EE, Kong HJ, Mooney DJ. Regulating myoblast phenotype through controlled gel stiffness and degradation. Tissue Eng 2007; 13: 1431-42.
14. Hammerick KE, Huang Z, Sun N, et al. Elastic properties of induced pluripotent stem cells. Tissue Eng Part A 2011; 17: 495-502.
15. Heunis TD, Dicks LM. Nanofibers offer alternative ways to the treatment of skin infections. J Biomed Biotechnol 2010; 2010: 510682.
16. Holzwarth JM, Ma PX. Biomimetic nanofibrous scaffolds for bone tissue engineering. Biomaterials 2011; 32: 9622-9.
17. Burg KJL, Porter S, Kellam JF. Biomaterial developments for bone tissue engineering. Biomaterials 2000; 21: 2347-59.
18. Place ES, Evans ND, Stevens MM. Complexity in biomaterials for tissue engineering. Nat Mater 2009; 8: 457-70.
19. Melkoumian Z, Weber JL, Weber DM, et al. Synthetic peptideacrylate surfaces for long-term self-renewal and cardiomyocyte differentiation of human embryonic stem cells. Nat Biotechnol 2010; 28: 606-10.
20. Mrksich M. Stem cell differentiation: Multipotency retained. Nat Mater 2011; 10: 559-60.
21. Kumbar SG, James R, Nukavarapu SP, Laurencin CT. Electrospun nanofiber scaffolds: engineering soft tissues. Biomed Mater 2008; 3: 034002.
22. Valmikinathan CM, Defroda S, Yu X. Polycaprolactone and bovine serum albumin based nanofibers for controlled release of nerve growth factor. Biomacromolecules 2009; 10: 1084-9.
23. Huang J, Elicker J, Bowens N, et al. Myocardin regulates BMP10 expression and is required for heart development. J Clin Invest 2012.
24. Okano J, Levy C, Lichti U, et al. Cutaneous retinoic acid levels determine hair follicle development and downgrowth. J Biol Chem 2012.
25. Wang P, Guo QS, Wang ZW, Qian HX. HBx induces HepG-2 cells autophagy through PI3K/Akt-mTOR pathway. Mol Cell Biochem 2012.
26. Rose FRAJ, Oreffo ROC. Bone Tissue Engineering: Hope vs Hype. Biochem Biophys Res Commun 2002; 292: 1-7.
27. Giannoudis PV, Einhorn TA. Bone morphogenetic proteins in musculoskeletal medicine. Injury 2009; 40, Supplement 3: S1-S3.
28. Gautschi OP, Frey SP, Zellweger R. Bone morphogenetic proteins in clinical applications. ANZ J Surg 2007; 77: 626-31.
29. Yue Z, Wen F, Gao S, et al. Preparation of three-dimensional interconnected macroporous cellulosic hydrogels for soft tissue engineering. Biomaterials 2010; 31: 8141-52.
30. Lee S, Shin H. Matrices and scaffolds for delivery of bioactive molecules in bone and cartilage tissue engineering. Adv Drug Deliv Rev 2007; 59: 339-59.
31. Lo KW, Ulery BD, Ashe KM, Laurencin CT. Studies of bone morphogenetic protein-based surgical repair. Adv Drug Deliv Rev 2012; 64: 1277-91.
32. Lo KW, Kan HM, Ashe KM, Laurencin CT. The small molecule PKA-specific cyclic AMP analogue as an inducer of osteoblast-like cells differentiation and mineralization. J Tissue Eng Regen Med 2012; 6: 40-8.
33. Lo KW, Ashe KM, Kan HM, Laurencin CT. The role of small molecules in musculoskeletal regeneration. Regen Med 2012; 7: 535-49.
34. Horiuchi N, Maeda T. Statins and bone metabolism. Oral Dis 2006; 12: 85-101.
35. Klein RF, Allard J, Avnur Z, et al. Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science 2004; 303: 229-32.
36. Raisz LG, Vanderhoek JY, Simmons HA, Kream BE, Nicolaou K. Prostaglandin synthesis by fetal rat bone in vitro: evidence for a role of prostacyclin. Prostaglandins 1979; 17: 905-14.
37. Tashjian AH, Tice JE, Sides K. Biological activities of prostaglandin analogues and metabolites on bone in organ culture. 1977.
38. Nancollas G, Tang R, Phipps R, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006; 38: 617-27.
39. Marie P, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001; 69: 121-9.
40. Garrett I, Chen D, Gutierrez G, et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003; 111: 1771-82.
41. Cortizo AM, Etcheverry SB. Vanadium derivatives act as growth factor--mimetic compounds upon differentiation and proliferation of osteoblast-like UMR106 cells. Mol Cell Biochem 1995; 145: 97-102.
42. Aydin E, Planell JA, Hasirci V. Hydroxyapatite nanorod-reinforced biodegradable poly(L-lactic acid) composites for bone plate applications. J Mater Sci Mater Med 2011; 22: 2413-27.
43. Barrere F, Mahmood TA, Groot K, Blitterswijk CA. Advanced biomaterials for skeletal tissue regeneration: Instructive and smart functions. Materials Science and Engineering R 2008: 38-71.
44. Crowley SJ, Eastman CI. Melatonin in the afternoons of a gradually advancing sleep schedule enhances the circadian rhythm phase advance. Psychopharmacology (Berl) 2012.
45. Mendez N, Abarzua-Catalan L, Vilches N, et al. Timed maternal melatonin treatment reverses circadian disruption of the fetal adrenal clock imposed by exposure to constant light. PLoS One 2012; 7: e42713.
46. Piesiewicz A, Kedzierska U, Podobas E, Adamska I, Zuzewicz K, Majewski PM. Season-dependent Postembryonic Maturation of the Diurnal Rhythm of Melatonin Biosynthesis in the Chicken Pineal Gland. Chronobiol Int 2012.
47. Barrell GK, Montgomery GW. Absence of circadian patterns of secretion of melatonin or cortisol in Weddell seals under continuous natural daylight. J Endocrinol 1989; 122: 445-9.
48. Cutando A, Gomez-Moreno G, Arana C, et al. Melatonin stimulates osteointegration of dental implants. J Pineal Res 2008; 45: 174-9.
49. Egermann M, Gerhardt C, Barth A, Maestroni GJ, Schneider E, Alini M. Pinealectomy affects bone mineral density and structure--an experimental study in sheep. BMC Musculoskelet Disord 2011; 12: 271.
50. Kotlarczyk MP, Lassila HC, O'Neil CK, et al. Melatonin osteoporosis prevention study (MOPS): a randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women. J Pineal Res 2012; 52: 414-26.
51. Lopez-Martinez F, Olivares Ponce PN, Guerra Rodriguez M, Martinez Pedraza R. Melatonin: bone metabolism in oral cavity. Int J Dent 2012; 2012: 628406.
52. Ramirez-Fernandez MP, Calvo-Guirado JL, de-Val JE, et al. Melatonin promotes angiogenesis during repair of bone defects: a radiological and histomorphometric study in rabbit tibiae. Clin Oral Investig 2012.
53. Muñoz F, López-Peña M, Miño N, Gómez-Moreno G, Guardia J, Cutando A. Topical Application of Melatonin and Growth Hormone Accelerates Bone Healing around Dental Implants in Dogs. Clin Implant Dent Relat Res 2012; 14: 226-35.
54. Roth JA, Kim BG, Lin WL, Cho MI. Melatonin promotes osteoblast differentiation and bone formation. J Biol Chem 1999; 274: 22041-7.
55. Conti A, Conconi S, Hertens E, Skwarlo-Sonta K, Markowska M, Maestroni JM. Evidence for melatonin synthesis in mouse and human bone marrow cells. J Pineal Res 2000; 28: 193-202.
56. Sinningen K, Tsourdi E, Rauner M, Rachner TD, Hamann C, Hofbauer LC. Skeletal and extraskeletal actions of denosumab. Endocrine 2012; 42: 52-62.
57. Koyama H, Nakade O, Takada Y, Kaku T, Lau KH. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. J Bone Miner Res 2002; 17: 1219-29.
58. Iguichi H, Kato KI, Ibayashi H. Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 1982; 55: 27-9.
59. Sack RL, Lewy AJ, Erb DL, Vollmer WM, Singer CM. Human melatonin production decreases with age. J Pineal Res 1986; 3: 379-88.
60. Ladizesky MG, Boggio V, Albornoz LE, Castrillon PO, Mautalen C, Cardinali DP. Melatonin increases oestradiol-induced bone formation in ovariectomized rats. J Pineal Res 2003; 34: 143-51.
61. Sanchez-Hidalgo M, Lu Z, Tan DX, Maldonado MD, Reiter RJ, Gregerman RI. Melatonin inhibits fatty acid-induced triglyceride accumulation in ROS17/2.8 cells: implications for osteoblast differentiation and osteoporosis. Am J Physiol Regul Integr Comp Physiol 2007; 292: R2208-15.
62. Satomura K, Tobiume S, Tokuyama R, et al. Melatonin at pharmacological doses enhances human osteoblastic differentiation in vitro and promotes mouse cortical bone formation in vivo. J Pineal Res 2007; 42: 231-9.
63. Radio NM, Doctor JS, Witt-Enderby PA. Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade. J Pineal Res 2006; 40: 332-42.
64. Zaminy A, Ragerdi Kashani I, Barbarestani M, Hedayatpour A, Mahmoudi R, Farzaneh Nejad A. Osteogenic differentiation of rat mesenchymal stem cells from adipose tissue in comparison with bone marrow mesenchymal stem cells: melatonin as a differentiation factor. Iran Biomed J 2008; 12: 133-41.
65. Park KH, Kang JW, Lee EM, et al. Melatonin promotes osteoblastic differentiation through the BMP/ERK/Wnt signaling pathways. J Pineal Res 2011; 51: 187-94.
66. Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS, Slominski AT. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol 2012; 351: 152-66.
67. Sethi S, Radio NM, Kotlarczyk MP, et al. Determination of the minimal melatonin exposure required to induce osteoblast differentiation from human mesenchymal stem cells and these effects on downstream signaling pathways. J Pineal Res 2010; 49: 222-38.
68. Zhang L, Zhang J, Ling Y,. Sustained release of melatonin from poly (lactic-co-glycolic acid) (PLGA) microspheres to induce osteogenesis of human mesenchymal stem cells in vitro. J Pineal Res 2012.
69. Aravamudhan A, Deng M, Toti U, et al. Induced Osteogenic differentiation of human mesenchymal stem cells by polymer nanofiber scaffolds in combination with melatonin. Proc Orthopaedic Res Soc Conference, San Francisco, California, USA 2012; pp. 1598.
70. Wu X, Walker J, Zhang J, Ding S, Schultz PG. Purmorphamine induces osteogenesis by activation of the hedgehog signaling pathway. Chem Biol 2004; 11: 1229-38.
71. St-Jacques B, Hammerschmidt M, McMahon AP. Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev 1999; 13: 2072-86.
72. Briscoe J. Agonizing hedgehog. Nat Chem Biol 2006; 2: 10-11.
73. Bijlsma MF, Peppelenbosch MP, Spek CA. Hedgehog morphogen in cardiovascular disease. Circulation 2006; 114: 1985-91.
74. Bolander ME. Regulation of fracture repair by growth factors. Proc Soc Exp Biol Med 1992; 200: 165-70.
75. Oda T, Notoya K, Gotoh M, et al. Synthesis of novel 2-benzothiopyran and 3-benzothiepin derivatives and their stimulatory effect on bone formation. J Med Chem 1999; 42: 751-60.
76. Beloti MM, Bellesini LS, Rosa AL. Purmorphamine enhances osteogenic activity of human osteoblasts derived from bone marrow mesenchymal cells. Cell Biol Int 2005; 29: 537-41.
77. Beloti MM, Bellesini LS, Rosa AL. The effect of purmorphamine on osteoblast phenotype expression of human bone marrow mesenchymal cells cultured on titanium. Biomaterials 2005; 26: 4245-8.
78. Pereira TS, Almeida-Palmas R, Gomes PS, Fernandes MH. Purmorphamine-induced osteoblastic commitment of adipose tissuederived mesenchymal cells. Bone 2009; 44, Supplement 2: S314-S315.
79. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
80. Mizutani K, Ikeda K, Kawai Y, Yamori Y. Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biochem Biophys Res Commun 1998; 253: 859-63.
81. Li Y, Danmark S, Edlund U, et al. Resveratrol-conjugated polyepsilon-caprolactone facilitates in vitro mineralization and in vivo bone regeneration. Acta Biomater 2011; 7: 751-8.
82. Dosier CR, Erdman CP, Park JH, Schwartz Z, Boyan BD, Guldberg RE. Resveratrol effect on osteogenic differentiation of rat and human adipose derived stem cells in a 3-D culture environment. Journal of the Mechanical Behavior of Biomedical Materials 2012; 11: 112-22.
83. Boissy P, Andersen TL, Abdallah BM, Kassem M, Plesner T, Delaisse JM. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res 2005; 65: 9943-52.
84. Su JL, Yang CY, Zhao M, Kuo ML, Yen ML. Forkhead proteins are critical for bone morphogenetic protein-2 regulation and antitumor activity of resveratrol. J Biol Chem 2007; 282: 19385-98.
85. Dai Z, Li Y, Quarles LD, et al. Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine 2007; 14: 806-14.
86. Backesjo CM, Li Y, Lindgren U, Haldosen LA. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J Bone Miner Res 2006; 21: 993-1002.
87. Chen HJ, Hsu LS, Shia YT, Lin MW, Lin CM. The betacatenin/ TCF complex as a novel target of resveratrol in the Wnt/beta-catenin signaling pathway. Biochem Pharmacol 2012; 84: 1143-53.
88. Zhou H, Shang L, Li X, et al. Resveratrol augments the canonical Wnt signaling pathway in promoting osteoblastic differentiation of multipotent mesenchymal cells. Exp Cell Res 2009; 315: 2953-62.
89. Peltz L, Gomez J, Marquez M, et al. Resveratrol exerts dosage and duration dependent effect on human mesenchymal stem cell development. PLoS One 2012; 7: e37162.
90. th World Biomaterial Congress, WBC, Chengdu, China, June 4-5, 2012; pp. 3137.
91. Andreou V, D'Addario M, Zohar R, et al. Inhibition of osteogenesis in vitro by a cigarette smoke-associated hydrocarbon combined with Porphyromonas gingivalis lipopolysaccharide: reversal by resveratrol. J Periodontol 2004; 75: 939-48.
92. Lee YM, Shin SI, Shin KS, Lee YR, Park BH, Kim EC. The role of sirtuin 1 in osteoblastic differentiation in human periodontal ligament cells. J Periodontal Res 2011; 46: 712-21.
93. Tseng PC, Hou SM, Chen RJ, et al. Resveratrol promotes osteogenesis of human mesenchymal stem cells by upregulating RUNX2 gene expression via the SIRT1/FOXO3A axis. J Bone Miner Res 2011; 26: 2552-63.
94. Uysal T, Gorgulu S, Yagci A, Karslioglu Y, Gunhan O, Sagdic D. Effect of resveratrol on bone formation in the expanded interpremaxillary suture: early bone changes. Orthod Craniofac Res 2011; 14: 80-7.
95. Singh H, James E, Kan HM, Nair LS. Fabrication and Evaluation of Resveratrol Loaded Polymeric Nanofibers. Journal of Biomaterials and Tissue Engineering 2012; 2: 228-35.
96. Emre N, Coleman R, Ding S. A chemical approach to stem cell biology. Curr Opin Chem Biol 2007; 11: 252-8.
97. Shakibaei M, Shayan P, Busch F, et al. Resveratrol mediated modulation of Sirt-1/Runx2 promotes osteogenic differentiation of mesenchymal stem cells: potential role of Runx2 deacetylation. PLoS One 2012; 7: e35712.